It is an oral medication containing dofetilide as the active ingredient. The formula also contains inactive ingredients of microcrystalline cellulose, corn starch, colloidal silicon dioxide, and magnesium stearate, gelatin, titanium dioxide, and FDC Yellow 6.
Clinical Uses of Dofetilide
Dofetilide is effective in maintaining sinus rhythm in patients with atrial fibrillation. In the DIAMOND studies (Torp-Pedersen C et al., 1999), dofetilide did not affect mortality in patients with advanced heart failure or those convalescing from acute myocardial infarction.
Dofetilide is indicated in adults for the conversion of atrial fibrillation or atrial flutter to normal sinus rhythm (NSR) and the preservation of normal sinus rhythm in patients with highly symptomatic atrial fibrillation or atrial flutter of more than one week whose pathological sinus rhythm has been converted to a normal.
Azimilide and Sematilide are also class III antiarrhythmics, but they are not available in the United States.
Because induction of severe ventricular arrhythmias is possible with dofetilide, it was available through a restricted distribution system that includes only physicians, hospitals, and other institutions that have received special educational programs covering proper dosing and in-hospital treatment initiation, which is called Risk Evaluation and Mitigation Strategy (REMS). However, in January 2016, although the safety risks for Tikosyn (dofetilide) continued to be present by FDA's determination, the agency also decided that REMS program are no longer compulsory because risk-benefit ration tilted on the side of benefits of the drug.
Off-Label Uses of Dofetilide
It has been used as an off-label prescription for supraventricular arrhythmias, ventricular tachycardia, and Wolff-Parkinson-White syndrome.
Just like other class III antiarrhythmic drugs, dofetilide blocks potassium channels in phase 3 of the action potential and slows the efflux of potassium cation back out of the myocyte, which slows the repolarization rate of the cell and widens the action potential's plateau phase. The refractory periods of atrial, ventricular, and Purkinje cells thereby are increased. This also leads to lengthening of the QT interval on the ECG. The increased widening of QT interval is possibly due to the inhibition of phosphoinositide 3–kinase, which increases the late sodium current (Yang T et al., 2014).
Dofetilide is a class III antiarrhythmic agent. By inhibiting a component of the time-dependent potassium current, dofetilide increases the effective refractory period and action potential without affecting the conduction velocity.
Dofetilide dosing is based on creatinine clearance: (CrCl greater than 60 mL/min) 500 mcg bid (CrCl 40 mL/min to 60 mL/min) 250 mcg bid; (CrCl 20 mL/min to less than 40 mL/min) 125 mcg bid; (CrCl less than 20 mL/min) contraindicated.
Safety and efficacy have not been established in children.
Route of Administration
Oral absorption approximately 100%.
Oral bioavailability is not affected by food or antacid. Steady-state plasma concentrations are attained within 2 to 3 days. Plasma concentrations are dose proportional.
Onset of Action
On a single dose, it takes 2 to 3 hours for dofetilide to reach maximum plasma concentration in the fasted state. Therefore, this means it takes 2 to 3 hours for the onset of action for dofetilide.
Duration of Action
The half-life of dofetilide was reported to be 4.8 to 13.5 hours. The most reported half-life in the literature is 10 hours for dofetilide. From a pharmacokinetic principle, it takes 4.5 to 5 half-lives to eliminate approximately 100% of a single dose administration of any drug. Hence, it takes 4.5 to 5 half-lives to eliminate a single dose of dofetilide from the human body, which is 45 to 50 hours. Therefore, duration of action of a single dose of dofetilide is 45 to 50 hours.
The volume of distribution: 3.1 L/kg to 4.0 L/kg. This indicates that dofetilide is not sequestered in fatty tissues.
Plasma protein binding of dofetilide is 60% to 70%, is independent of plasma concentration, and is unaffected by renal impairment. The volume of distribution: 3.1 L/kg to 4.0 L/kg.
Fifty percent of dofetilide is metabolized in the liver into inactive metabolites. Dofetilide is metabolized to a small extent by the CYP3A4 isoenzyme of the cytochrome P450 system. Inhibitors of the CYP3A4 isoenzyme could increase systemic dofetilide exposure. Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazodone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with Tikosyn as they can potentially increase dofetilide levels. Dofetilide is not an inhibitor of CYP3A4 nor of other cytochrome P450 isoenzymes (e.g., CYP2C9, CYP2D6) and is not expected to increase levels of drugs metabolized by CYP3A4.
About 80% of a single dose of dofetilide is excreted in urine with 80% as unchanged drug and the remaining 20% consisting of inactive or minimally active metabolites. Dofetilide is eliminated in the kidney by cationic secretion. Inhibitors of renal cationic secretion are contraindicated with dofetilide (Tikosyn). In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels. Elimination half-life is 4.8 to 13.5 hours.
The drug has virtually no extracardiac pharmacological effects.
Torsades de pointes occurred in 1% to 3% of patients in clinical trials where strict exclusion criteria (e.g., hypokalemia) were applied, and continuous ECG monitoring was used to detect marked QT prolongation in the hospital.
With therapeutic use, dofetilide may induce or worsen ventricular dysrhythmias, producing life-threatening polymorphic ventricular tachycardia. Patients with a history of torsade de pointes, prolonged QTc (greater than 440 milliseconds), hypomagnesemia or serum potassium below 4.0 mEq/L are at increased risk of developing ventricular dysrhythmias. Other adverse effects that may occur with dofetilide administration include chest pain, nausea, abdominal pain, flatulence, diarrhea, headache, dizziness, and fatigue.
Overdose experience is limited. Effects reported include QT prolongation, torsade de pointes and complete heart block. Most common side effects are a headache, chest pain and dizziness.
Adverse Reactions Severe
Adverse Reactions Mild
Dofetilide is classified as FDA pregnancy category C. Therefore, should not be given to a pregnant patient.
Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide with the remaining 20% consisting of inactive or minimally active metabolites. Renal elimination involves both glomerular filtration and active tubular secretion (via the cation transport system, a process that can be inhibited by cimetidine, trimethoprim, prochlorperazine, megestrol, ketoconazole, and dolutegravir). In vitro studies with human liver microsomes show that CYP3A4 can metabolize dofetilide, but it has a low affinity for this isoenzyme. N-dealkylation and N-oxidation form metabolites.
The following list of drugs are known to have significant interactions with dofetilide because renal elimination could be inhibited:
Cimetidine (Tagamet, Tagamet HB)*
Verapamil (Calan, Calan SR, Covera-HS, Isoptin, Isoptin SR, Verelan, Verelan PM, Tarka)*
Ketoconazole (Nizoral, Xolegel, Extina)*
Trimethoprim alone (Proloprim, Trimpex)* or the combination of
Trimethoprim and sulfamethoxazole (Bactrim, Septra Sulfatrim)*
Prochlorperazine (Compazine, Compo)*
Hydrochlorothiazide alone or in combination with other medicines (such as Esidrix, Ezide, Hydrodiuril, Hydro-Par, Microzide, or Oretic)*
Dofetilide is contraindicated in patients with long QT syndrome. It is also contraindicated in patients who are on kidney dialysis or have renal diseases.
Dofetilide is contraindicated in patients having a low level of potassium in the blood, vomiting and/or diarrhea, sweating, loss of appetite, or decreased thirst, and whether the patients have or have ever had have heart or liver disease. Dofetilide is contraindicated in patients planning to become pregnant, pregnant or who are breastfeeding.
Therapeutic Effects of Dofetilide
Dofetilide may induce or worsen ventricular dysrhythmias, producing life-threatening polymorphic ventricular tachycardia. Patients with a history of torsade de pointes, prolonged QTc (greater than 440 milliseconds), hypomagnesemia or serum potassium below 4.0 mEq/L are at increased risk of developing ventricular dysrhythmias. Other adverse effects that may occur during dofetilide administration include chest pain, nausea, abdominal pain, flatulence, diarrhea, headache, dizziness, and fatigue.
Central Nervous System Effects
Headache, dizziness, syncope, paresthesia, insomnia, anxiety, migraine, cerebral ischemia, facial paralysis, CVA.
Ventricular fibrillation, ventricular tachycardia, torsades de pointes, AV block, chest pain, bradycardia, edema, cardiac arrest, sudden death, MI, QT prolongation, atrial fibrillation, hypertension.
Adequate ventilation should be ensured, and endotracheal intubation performed early in patients with life-threatening cardiac arrhythmias.
Additional Monitoring Requirements/Precautions
All class III (potassium channel blockers) antiarrhythmic drugs are proarrhythmia as well. Therefore, extreme care should be taken by physicians when prescribing dofetilide for patients.
Toxic manifestations are usually an extension of the pharmacological activity (torsade de pointes). Oral dofetilide doses of 500 mcg twice daily have been associated with an increased risk of developing torsades de pointes; sudden death has been reported in one patient. A patient received two 500 mcg dofetilide doses one hour apart and developed ventricular fibrillation and cardiac arrest 2 hours after the second dose. During a clinical study, one subject ingested 28 500 mcg capsules and was treated with gastric lavage within 30 minutes of exposure. No adverse effects were reported.
The most likely side effect of overdose is the excessive lengthening of the QT interval.
There is no known remedy for dofetilide overdoses; treatment of dofetilide overdose is supportive and symptomatic. Start cardiac monitoring with ECG. A charcoal slurry given within first 15 minutes of administration is useful. Pharmacological management of dofetilide overdose and Torsades de Pointes may include isoproterenol, with or without cardiac pacing and magnesium sulfate. But beta-blockers have also been used.
|Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter., Abraham JM,Saliba WI,Vekstein C,Lawrence D,Bhargava M,Bassiouny M,Janiszewski D,Lindsay B,Militello M,Nissen SE,Poe S,Tanaka-Esposito C,Wolski K,Wilkoff BL,, Circulation. Arrhythmia and electrophysiology, 2015 Aug [PubMed PMID: 26063741]|
|Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current., Yang T,Chun YW,Stroud DM,Mosley JD,Knollmann BC,Hong C,Roden DM,, Circulation, 2014 Jul 15 [PubMed PMID: 24895457]|
|Drug block of I(kr): model systems and relevance to human arrhythmias., Yang T,Snyders D,Roden DM,, Journal of cardiovascular pharmacology, 2001 Nov [PubMed PMID: 11602820]|
|Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group., Møller M,Torp-Pedersen CT,Køber L,, Congestive heart failure (Greenwich, Conn.), 2001 May-Jun [PubMed PMID: 11828153]|
|Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group., Torp-Pedersen C,Møller M,Bloch-Thomsen PE,Køber L,Sandøe E,Egstrup K,Agner E,Carlsen J,Videbaek J,Marchant B,Camm AJ,, The New England journal of medicine, 1999 Sep 16 [PubMed PMID: 10486417]|
|Recent Advances in the Pharmacological Management of Atrial Fibrillation., Gooden JY,Powell BD,Akogyeram CO,Melduni RM,, American journal of therapeutics, 2016 Jan-Feb [PubMed PMID: 23689090]|
|Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms., Hanley CM,Robinson VM,Kowey PR,, Circulation. Arrhythmia and electrophysiology, 2016 Mar [PubMed PMID: 26936819]|
|Quantitative Comparison of Effects of Dofetilide, Sotalol, Quinidine, and Verapamil between Human <i>Ex vivo</i> Trabeculae and <i>In silico</i> Ventricular Models Incorporating Inter-Individual Action Potential Variability., Britton OJ,Abi-Gerges N,Page G,Ghetti A,Miller PE,Rodriguez B,, Frontiers in physiology, 2017 [PubMed PMID: 28868038]|
|2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society., January CT,Wann LS,Alpert JS,Calkins H,Cigarroa JE,Cleveland JC Jr,Conti JB,Ellinor PT,Ezekowitz MD,Field ME,Murray KT,Sacco RL,Stevenson WG,Tchou PJ,Tracy CM,Yancy CW,, Journal of the American College of Cardiology, 2014 Dec 2 [PubMed PMID: 24685669]|
|2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society., January CT,Wann LS,Alpert JS,Calkins H,Cigarroa JE,Cleveland JC Jr,Conti JB,Ellinor PT,Ezekowitz MD,Field ME,Murray KT,Sacco RL,Stevenson WG,Tchou PJ,Tracy CM,Yancy CW,, Circulation, 2014 Dec 2 [PubMed PMID: 24682348]|
|2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society., January CT,Wann LS,Alpert JS,Calkins H,Cigarroa JE,Cleveland JC Jr,Conti JB,Ellinor PT,Ezekowitz MD,Field ME,Murray KT,Sacco RL,Stevenson WG,Tchou PJ,Tracy CM,Yancy CW,, Circulation, 2014 Dec 2 [PubMed PMID: 24682347]|